FlupentixolThird Party Manufacturing in India

Flupentixol works by antagonising dopamine D1 and D2 receptors in the central nervous system, a mechanism characteristic of thioxanthene antipsychotics. By blocking dopamine-mediated neurotransmission in the mesolimbic and mesocortical pathways, flupentixol reduces the positive symptoms of schizophrenia such as hallucinations, delusions, and thought disorders. The drug exists as two geometric isomers, with the cis(Z)-flupentixol being the pharmacologically active form that contributes to its therapeutic effects. At lower doses, flupentixol exhibits anxiolytic and antidepressant properties through preferential blockade of presynaptic dopamine autoreceptors, which paradoxically enhances dopamine release in certain brain regions. This dose-dependent dual action makes flupentixol unique among antipsychotics, allowing its use across a spectrum of psychiatric conditions from anxiety to schizophrenia. The drug also exhibits moderate affinity for serotonin 5-HT2 and histamine H1 receptors, which contributes to its side effect profile but does not significantly impact its therapeutic efficacy. Unlike typical antipsychotics, flupentixol has relatively low affinity for muscarinic cholinergic receptors, resulting in fewer anticholinergic side effects. Its decanoate ester form allows for long-acting intramuscular depot administration, providing sustained therapeutic coverage for patients with poor medication compliance.

Therapeutic Uses

Flupentixol is prescribed for the treatment of:

• Schizophrenia: Flupentixol is indicated for the management of chronic schizophrenia, particularly in patients whose predominant symptoms are not excitement, agitation, or hyperactivity. It effectively controls positive symptoms while having a lower propensity for sedative effects compared to other antipsychotics.

• Depression with Anxiety: At lower doses, flupentixol is used as an adjunctive treatment for depression accompanied by anxiety symptoms. Its activating properties at low doses make it suitable for patients with psychomotor retardation.

• Psychosomatic Disorders: Flupentixol is prescribed for psychosomatic complaints where anxiety and depressive features contribute to somatic symptoms.

• Maintenance Therapy: As a long-acting depot injection (flupentixol decanoate), it is used for maintenance treatment in schizophrenia patients with poor compliance to oral medication.

Why Manufacturers Choose Flupentixol

Flupentixol is an established antipsychotic molecule with steady demand from psychiatric care facilities and PCD franchise networks in India. The molecule is available in multiple dosage strengths (0.5mg, 1mg, 3mg tablets) allowing for flexible dosing from anxiolytic to antipsychotic levels. Indian manufacturers benefit from the well-characterised synthesis pathway and the availability of pharmaceutical-grade raw materials. Both oral tablet and long-acting injectable forms are manufactured in India, though tablets remain the most common for third party manufacturing arrangements. The molecule's presence on WHO Essential Medicines List for select countries reinforces its clinical importance. For contract manufacturing partners, flupentixol offers consistent year-round demand with established distribution channels through psychiatric PCD franchise networks across India and select export markets.